Answers are grounded in this paper and cite their sources.
The thiol proteinase inhibitor in human plasma (and serum) was separated into 3 forms [P-1(S-1), P-2(S-2), and P-3(S-3)] by linear gradient elution on a DEAE cellulose column. The individual inhibitors were purified to a functionally pure state by gel filtration on a Sephadex G-150 column, starch block electrophoresis and affinity chromatography on a trypsin-chymotrypsin-Chromagel A-2 column. The largest molecular weight inhibitor P-3 was further purified by chromatography on an anti-albumin column and by preparative polyacrylamide gel electrophoresis; the final preparation appeared homogeneous by immunoelectrophoresis and analytical polyacrylamide gel electrophoresis. Monospecific antiserum against P-3 was prepared by immunizing rabbits with purified P-3. The three forms of inhibitor showed similar pH stability curves and inhibition spectra on the proteolytic (casein substrate) and amidase (Bz-Arg-pNA, and Bz-Tyr-pNA) activities of ficin, papain, trypsin, and chymotrypsin. Moreover, the antibody against P-3 suppressed the inhibitory activities of P-1, P-2, and P-3 to similar extents in various antibody concentrations, and no spur was formed between the precipitin lines of the three forms against antiP-3 antibody by double immunodiffusion. However, the three forms differed in molecular weight and isoelectric point [mol. wt. and pI for P-1(S-1), 90,000 and 4.5 (85,000 and 4.45); for P-2(S-2), 95,000 and 4.4 (94,000 and 4.35); for P-3(S-3), 167,000 and 4.1 (150,000 and 4.0)]. P-3 was the most heat-stable, showing no decrease in inhibitory activity when heated up to 70°C for 1 h; P-1 and P-2 were stable up to 50°C. P-1(S-1) and P-2(S-2) migrated in the α1-region and P-3(S-3) in the a1-region in accordance with the difference in their isoelectric points. Thus, the term α1-TPJ is recommended for P-3(S-3), and the terms α2-TPI1 and α2 -TPI, for P-2(S-2) and P-1(S-1), respectively. These data indicate that human plasma contains three different forms of thiol proteinase inhibitor, which have the same antigenicity.
No takes yet. Share an insight, caveat, or question.
Sasaki et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: